Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has been granted a patent in Japan for its work around the Compositions and Methods for Treating Chronic Kidney Disease with drug NP-251 or Repirinast.
Moreau telling Proactive this now repurposed drug was approved in the Japanese market for the treatment of asthma and this is now quite significant for its approval for use in the treatment of renal fibrosis or kidney disease.
Repirinast has data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to medicine blood pressure drug telmisartan in a unilateral ureteral obstruction mouse model.
Contact Details
Proactive Canada
+1 604-688-8158
